Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature

Journal of the American College of Cardiology

Volumn 32, Issue 1, 1998, Pages 117-122

  Stein, C Michael ^a   Brown, Nancy ^a   Vaughan, Douglas E ^a   Lang, Chim C ^a   Wood, Alastair J j ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; ISOPRENALINE; METHACHOLINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADRENERGIC STIMULATION; ADULT; ARTICLE; CLINICAL TRIAL; FIBRINOLYSIS; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SHEAR STRESS; THROMBOSIS; VASCULAR ENDOTHELIUM;

ADULT; BLOOD FLOW VELOCITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; ISOPROTERENOL; MALE; METHACHOLINE CHLORIDE; NITRIC OXIDE; NITROPRUSSIDE; PARASYMPATHOMIMETICS; PLASMINOGEN INACTIVATORS; RADIAL ARTERY; SYMPATHOMIMETICS; TISSUE PLASMINOGEN ACTIVATOR; VASODILATOR AGENTS;

EID: 0032127738     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00210-1     Document Type: Article

References (34)

1. Hamsten A., Walldius G., Szamosi A., et al. Plasminogen activator inhibitor in plasma risk factor for recurrent myocardial infarction . Lancet. 2:1987;3-9.
2. Jansson J.H., Olofsson B.O., Nilsson T.K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation. 88:1993;2030-2034.
3. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., Hennekens C.H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 341:1993;1165-1168.
4. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
5. Margaglione M., Di Minno G., Grandone E., et al. Abnormally high levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol. 14:1994;1741-1745.
6. Panza J.A., Quyyumi A.A., Brush J.E., Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 323:1990;22-27.
7. Linder L., Kiowski W., Buhler F.R., Luscher T.F. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo blunted response in essential hypertension . Circulation. 81:1990;1762-1767.
8. Kubo S.H., Rector T.S., Bank A.J., Williams R.E., Heifetz S.M. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 84:1991;1589-1596.
9. Creager M.A., Cooke J.P., Mendelson M.E., et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 86:1990;228-234.
10. Klocking H.P. Release of plasminogen activator by acetylcholine from the isolated perfused pig ear. Thromb Res. 16:1979;261-264.
11. Emeis J.J. Perfused rat hindlegs. A model to study plasminogen activator release. Thromb Res. 30:1983;195-203.
12. Zhu G.J., Abbadini M., Donati M.B., Mussoni L. Tissue-type plasminogen activator release in response to epinephrine in perfused rat hindlegs. Am J Physiol. 256:1989;H404-H410.
13. Chandler W.L., Levy W.C., Veith R.C., Stratton J.R. A kinetic model of the circulatory regulation of tissue-type plasminogen activator during exercise, epinephrine infusion, and endurance training. Blood. 81:1993;3293-3302.
14. Chandler W.L., Levy W.C., Stratton J.R. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation. 92:1995;2984-2994.
15. Cash J.D., Woodfield D.G., Allan A.G.E. Adrenergic mechanisms in the systemic plasminogen activator response to adrenaline in man. Br J Haematol. 18:1970;487-494.
16. Gader A.M.A., Clarkson A.R., Cash J.D. The plasminogen activator and coagulation factor VII responses to adrenaline, noradrenaline, isoprenaline and salbutamol in man. Thromb Res. 2:1973;9-16.
17. de Boer A., Cluft C., Kroon J.M., et al. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 67:1992;83-87.
18. Jern C., Selin L., Jern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb Haemost. 72:1994;285-291.
19. Jern S., Selin L., Bergbrant A., Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost. 72:1994;588-594.
20. Lang C.C., Stein C.M., Brown R.M., et al. Attenuation of isoproterenol-mediated vasodilation in blacks. N Engl J Med. 333:1995;155-160.
21. Stein C.M., Lang C.C., Nelson R., Brown M., Wood A.J.J. Vasodilation in African-Americans attenuated nitric oxide-mediated responses . Clin Pharmacol Ther. 62:1997;436-443.
22. Whitney R.J. The measurement of volume changes in human limbs. J Physiol. 121:1953;1-27.
23. Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., Vaughan D.E. Stimulation of plasminogen-activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 87:1993;1969-1973.
24. Keber D., Stegnar M., Kluft C. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Throm Haemost. 63:1990;72-75.
25. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide physiology, pathophysiology and pharmacology . Pharmacol Rev. 43:1991;109-142.
26. Diamond S.L., Eskin S.G., McIntire L.V. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science. 243:1989;1483-1485.
27. Newby D.E., Wright R.A., Ludlam C.A., Fox K.A.A., Webb D.J. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Throm Haemost. 78:1997;1242-1248.
28. Kruithof E.K., Tran-Thang C., Ransijn A., Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood. 64:1984;907-913.
29. van den Eijnden-Schrauwen Y., Kooistra T., de Vries R.E.M., Emeis J.J. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo evidence of a dynamic storage pool . Blood. 85:1995;3510-3517.
30. Parmer R.J., Mahata M., Mahata S., Sebald M.T., O'Connor D.T., Miles L.A. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. J Biol Chem. 272:1997;1976-1982.
31. Stein M., Deegan R., He H., Wood A.J.J. Beta-adrenergic receptor mediated release of norepinephrine in the human forearm. Clin Pharmacol Ther. 54:1993;58-64.
32. Dawes M., Chowienczyk P.J., Ritter J.M. Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Circulation. 95:1997;2293-2297.
33. Naslund T., Silbertstein D.J., Merrell W.J., Nadeau J.H., Wood A.J.J. Low sodium intake corrects abnormality in beta-receptor mediated arterial vasodilation in patients with hypertension correlation with beta-receptor function in vitro . Clin Pharmacol Ther. 48:1990;87-95.
34. Stein C.M., Nelson R., Deegan R., He H., Wood M., Wood A.J.J. Forearm beta adrenergic receptor-mediated vasodilation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension. J Clin Invest. 96:1995;579-585.